Document Detail

Targeted immunotherapy of cancer with CAR T cells: achievements and challenges.
MedLine Citation:
PMID:  22527245     Owner:  NLM     Status:  Publisher    
The adoptive transfer of chimeric antigen receptor (CAR)-expressing T cells is a relatively new but promising approach in the field of cancer immunotherapy. This therapeutic strategy is based on the genetic reprogramming of T cells with an artificial immune receptor that redirects them against targets on malignant cells and enables their destruction by exerting T cell effector functions. There has been an explosion of interest in the use of CAR T cells as an immunotherapy for cancer. In the pre-clinical setting, there has been a considerable focus upon optimizing the structural and signaling potency of the CAR while advances in bio-processing technology now mean that the clinical testing of these gene-modified T cells has become a reality. This review will summarize the concept of CAR-based immunotherapy and recent clinical trial activity and will further discuss some of the likely future challenges facing CAR-modified T cell therapies.
Grazyna Lipowska-Bhalla; David E Gilham; Robert E Hawkins; Dominic G Rothwell
Related Documents :
8694505 - Variations in energy and phospholipid metabolism in normal and cancer human mammary epi...
753385 - Ultrastructural changes in cells of transplanted mammary gland carcinoma at different s...
17360445 - Interaction with the mammary microenvironment redirects spermatogenic cell fate in vivo.
18585375 - Genetic mosaic analysis reveals fgf receptor 2 function in terminal end buds during mam...
22200735 - Dynein regulates cell migration depending on substrate rigidity.
19407015 - In vitro evidence of nerve growth factor effects on human conjunctival epithelial cell ...
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2012-4-22
Journal Detail:
Title:  Cancer immunology, immunotherapy : CII     Volume:  -     ISSN:  1432-0851     ISO Abbreviation:  -     Publication Date:  2012 Apr 
Date Detail:
Created Date:  2012-4-24     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8605732     Medline TA:  Cancer Immunol Immunother     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Clinical and Experimental Immunotherapy Group, School of Cancer and Enabling Sciences, Manchester Academic Health Science Centre, University of Manchester, Manchester, UK.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  The roles of mast cells in anticancer immunity.
Next Document:  Activation-induced cytidine deaminase (AID) linking immunity, chronic inflammation, and cancer.